Rodrigo Dienstmann

Universitat de Vic - Universitat Central de Catalunya

Also affiliated with Hebron University, MedSIR (Spain), Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari, Sociedade Brasileira de Oncologia Clínica, Vall d'Hebron Institute of Oncology

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 1%percentile

4.9Author DataRank

Indexed papers

3in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 3 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

A harmonized meta-knowledgebase of clinical interpretations of somatic genomic variants in cancer

Nature Genetics(2020)10.1038/s41588-020-0603-8

Top 4%

4.9DataRank

Top 4%178 citations

Brian Walsh, Georgia Mayfield, David Tamborero, Dmitriy Sonkin, Kilannin Krysiak +34 more

Papers

Driven by 11 papers — median percentile 96. Top paper: “A harmonized meta-knowledgebase of clinical interpretations of somatic genomic variants in cancer”.

A harmonized meta-knowledgebase of clinical interpretations of somatic genomic variants in cancer

Nature Genetics(2020)10.1038/s41588-020-0603-8

Top 4%

4.9DataRank

Top 4%178 citations

Brian Walsh, Georgia Mayfield, David Tamborero, Dmitriy Sonkin, Kilannin Krysiak +34 more

High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer

Nature Communications(2022)10.1038/s41467-022-32828-6

N/A

0.721DataRank · unranked

121 citations

Laia Monserrat, Meritxell Bellet, Guillermo Villacampa, Abel González-Pérez, Mafalda Oliveira +33 more

Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-19-3324

N/A

0.561DataRank · unranked

41 citations

Marta Palafox, Laia Monserrat, Fara Brasó‐Maristany, Andreu Òdena, Mònica Sánchez-Guixé +26 more

Development of a prognostic model to predict 90-day mortality in hospitalised cancer patients (PROMISE tool): a prospective observational study

The Lancet Regional Health - Europe(2024)10.1016/j.lanepe.2024.101063

N/A

0.292DataRank · unranked

6 citations

Berta Martin-Cullell, Vı́ctor Navarro, Kreina Sharela Vega, Jordi Recuero-Borau, Diego Gómez-Puerto +37 more

Challenges and Opportunities in Building a Health Economic Framework for Personalized Medicine in Oncology

Personalized Medicine(2023)10.2217/pme-2022-0008

N/A

0.267DataRank · unranked

4 citations

Silvio Matsas, Rodrigo Dienstmann, Carlos Gil Ferreira, Pedro Nazareth Aguiar

Frequency and spectrum of CHEK2 variants in a large Brazilian set of germline-tested patients.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.e22539

N/A

0.165DataRank · unranked

2 citations

Carolina de Bustamante Fernandes, Ana Carolina Branco Neves Silva, Fernanda Orpinelli Ramos do Rego, Fernanda Christtanini Koyama, Layla Testa Galindo +15 more